8-K: CVRx Posts 2025 Revenue Growth, Launches Major Heart Trial

CVRx, Inc. announced its fourth quarter and full year 2025 financial results, highlighting revenue growth and the initiation of the landmark BENEFIT-HF trial.

Summary

• Total revenue for the fourth quarter of 2025 was $16.0 million, an increase of 4% over the prior year quarter.
• U.S. revenue for the fourth quarter of 2025 was $14.9 million, an increase of 4% over the prior year quarter.
• Total revenue for the full year 2025 was $56.7 million, an increase of 10% over the prior year.
• Active implanting centers in the U.S. grew to 252 in 2025, compared to 223 in the prior year.
• The BENEFIT-HF trial was initiated in January 2026, with first enrollments expected in the second quarter of 2026.
• Category I CPT codes and related favorable physician fee payment levels took effect on January 1, 2026, removing automatic prior authorization denials.
• Gross profit for Q4 2025 was $13.8 million, an 8% increase, with gross margin rising to 86% from 83% in Q4 2024.
• Net loss for Q4 2025 was $11.9 million, or $0.46 per share, compared to a net loss of $10.7 million, or $0.43 per share, in Q4 2024.
• Net loss for the full year 2025 was $53.3 million, or $2.04 per share, an improvement from $60.0 million, or $2.65 per share, in 2024.
• Cash and cash equivalents were $75.7 million as of December 31, 2025.
• Net cash used in operating and investing activities was $40.8 million for the full year 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report. While Q4 revenue growth slowed and net loss increased, the full-year performance showed solid growth and improved net loss. Strategic initiatives like the BENEFIT-HF trial and CPT code changes offer significant future growth potential and market expansion.

Positives

• Consistent revenue growth, with 10% for the full year 2025 ($56.7 million) and 4% in Q4 2025 ($16.0 million).
• Improved gross margin to 86% in Q4 2025 and 85% for the full year 2025, driven by increased average selling price and manufacturing efficiencies.
• Expansion of active U.S. implanting centers to 252 in 2025, up from 223 in 2024, indicating broader market penetration.
• Initiation of the BENEFIT-HF trial, a landmark study that could potentially triple the addressable market for Barostim therapy.
• New Category I CPT codes effective January 1, 2026, are expected to remove automatic prior authorization denials, facilitating patient access.
• Full year net loss decreased to $53.3 million in 2025 from $60.0 million in 2024, showing an improvement in overall profitability trend.
• Amended debt facility provides additional capital flexibility, increasing the available facility by $50 million to $100 million.

Negatives

• Net loss increased in Q4 2025 to $11.9 million ($0.46 per share) compared to $10.7 million ($0.43 per share) in Q4 2024.
• Research and development expenses increased by 7% to $3.0 million in Q4 2025, primarily due to increased headcount.
• Selling, general and administrative expenses increased by 9% to $22.0 million in Q4 2025, mainly due to increased headcount, advertising, and travel expenses.
• Cash and cash equivalents decreased from $105.9 million at December 31, 2024, to $75.7 million at December 31, 2025.
• Net cash used in operating and investing activities remained high at $40.8 million for the full year 2025.
• Other income, net decreased in both Q4 2025 and full year 2025, primarily due to less interest income on interest-bearing accounts.

Risks

• Expectation of continued significant losses.
• Limited history operating as a commercial company and dependence on a single product, Barostim.
• Limited commercial sales experience marketing and selling Barostim.
• Ability to continue demonstrating to physicians and patients the merits of Barostim.
• Any failure by third-party payors to provide adequate coverage and reimbursement for the use of Barostim.
• Competitors' success in developing and marketing products that are safer, more effective, less costly, easier to use, or otherwise more attractive than Barostim.
• Any failure to receive access to hospitals.
• Dependence upon third-party manufacturers and suppliers, and in some cases a limited number of suppliers.
• A pandemic, epidemic, or outbreak of an infectious disease in the U.S. or worldwide.
• Product liability claims.
• Future lawsuits to protect or enforce intellectual property, which could be expensive, time-consuming, and ultimately unsuccessful.
• Any failure to retain key executives or recruit and hire new employees.
• Impacts on adoption and regulatory approvals resulting from additional long-term clinical data about the product.

Future Outlook

For the full year 2026, CVRx expects total revenue between $63.0 million and $67.0 million, gross margin between 84% and 86%, and operating expenses between $103.0 million and $107.0 million. For the first quarter of 2026, total revenue is expected to be between $13.7 million and $14.7 million. The BENEFIT-HF trial is expected to begin enrollment in the second quarter of 2026, with net trial costs projected to be $20 million to $30 million spread over the next five to seven years, potentially tripling the addressable market for Barostim.

Management Comments

• "We achieved key foundational goals in 2025, and we're heading into 2026 with increasing momentum."
• "Our sales team is building experience and becoming more effective, and we're seeing strong support at high-potential centers."
• "Additionally, the new Category I CPT codes, effective January 1st, remove automatic prior authorization denials."
• "Finally, the initiation of the landmark BENEFIT-HF trial under CMS Category B IDE coverage is a major step that could allow us to triple our addressable market."
• "We're confident that these developments will support our accelerated growth and make Barostim therapy more accessible for heart failure patients in the coming year."

Industry Context

StockSavvy.ai notes that CVRx operates in the growing neuromodulation medical device sector, specifically targeting cardiovascular diseases like heart failure. The initiation of the BENEFIT-HF trial and the new CPT codes are significant developments that could enhance market access and adoption for Barostim, positioning CVRx to potentially capture a larger share of the heart failure treatment market, which is a substantial and underserved area. The focus on expanding the indicated patient population aligns with broader industry trends of seeking broader applications for approved therapies.

Stakeholder Impact

• Shareholders: Potential for increased value through market expansion (BENEFIT-HF trial) and improved access (CPT codes), but continued losses and cash burn pose risks.
• Employees: Increased headcount in R&D and SG&A suggests growth in employment opportunities.
• Customers (Hospitals/Physicians): Expansion of active implanting centers and removal of prior authorization denials for CPT codes should ease adoption and use of Barostim.
• Patients: The BENEFIT-HF trial aims to expand Barostim's indication, potentially making the therapy accessible to a significantly larger population of heart failure patients.
• Creditors (Innovatus Capital Partners): Amended term loan agreement indicates continued relationship and increased debt facility.

Next Steps

• First enrollments in the BENEFIT-HF trial are expected to begin in the second quarter of 2026.
• The company will host a conference call on February 12, 2026, at 4:30 p.m. Eastern Time to review its results.

Key Dates

Recommendation

While CVRx demonstrated solid full-year revenue growth and improved gross margins, the Q4 slowdown in revenue growth and increased net loss are concerns. The initiation of the BENEFIT-HF trial and the positive impact of new CPT codes are significant long-term catalysts, but the company continues to operate at a loss and burn cash. The increased debt facility provides liquidity, but the path to profitability remains unclear. Investors should hold to monitor the progress of the BENEFIT-HF trial and the impact of the CPT code changes on sales acceleration.

Keywords

CVRx, CVRX, Barostim, neuromodulation, heart failure, medical device, cardiovascular disease, financial results, Q4 2025, full year 2025, BENEFIT-HF trial, CPT codes, SEC filing, 8-K